The Fc fusion therapeutics market is anticipated to grow at an annualized rate of over 10%, claims Roots Analysis

Since the approval of Enbrel® in 1998 for the treatment of rheumatoid arthritis, Fc fusion therapies have evolved into a prominent class of therapeutics; currently, several therapies are being developed for a variety of disease indications.

For additional details, please visit
https://www.rootsanalysis.com/reports/fc-fusion-therapeutics-market.html
 

comments (0)

46 more from jameshebrew